Biotech founder and CEO Jan Jensen has never been one for following the beaten track. As a young scientist studying the formation of insulin-producing pancreatic cells, Jensen questioned the prevailing view that these cells descended from neuroectoderm. His pancreatic embryonic tissue studies told him otherwise: insulin-producing pancreatic cells originate from within the pancreas itself. Jensen’s hypothesis, now the accepted view, and his further studies made him the first developmental biologist at Novo Nordisk, at a time when the world’s largest insulin producer had little interest in cell-based therapy. Now, 20 years later, Novo Nordisk is at the forefront of cell-based Type I Diabetes research. [Read more…]
Gameto Announces New Data Demonstrating Clinical-Grade Manufacturing of In Vitro Maturation Solution for Fertility Care
Manuscript demonstrates Gameto’s manufacturing process resulted in ovarian support cells of improved efficacy, quality and safety for in vitro maturation applications
NEW YORK, May 8, 2024 — Gameto, a female-led biotechnology company with a mission to redefine women’s healthcare, announced new research outlining the cellular engineering and manufacturing techniques underlying Fertilo, their novel investigational in vitro maturation (IVM) solution containing engineered ovarian support cells (OSCs) to mature eggs outside of the body. These data underscore that Gameto’s quality by design strategic product development supports the manufacturing of OSC-IVM for clinical and commercial use. [Read more…]
Further CYP-001 GvHD Clinical Data Published in Nature Medicine
Two-year overall survival rate in patients with steroid-resistant acute GvHD was 60%
Melbourne, Australia; 22 May 2024 — Cynata Therapeutics Limited (ASX: “CYP”, “Cynata”, or the “Company”), a clinical-stage biotechnology company specialising in cell therapeutics, is pleased to announce the publication of two-year follow-up data of CYP-001 in patients with steroid-resistant acute graft versus host disease (SR-aGvHD) in the prestigious peer-reviewed journal Nature Medicine.
CYP-001 is Cynata’s Cymerus™ off-the-shelf iPSC[i]-derived MSC[ii] product for intravenous infusion, which is being investigated as a potential immune modulating treatment. [Read more…]
Bayer and Evotec to Develop Precision Cardiology Therapeutics Using iPSC-based Disease Modelling
Bayer and Evotec Update Focus of their Collaboration to Cardiovascular Diseases
Strategic Alliance will Leverage Human iPSC Disease Modelling for Identification of Novel Targets
Berlin and Hamburg, Germany, 30 April 2024 – Bayer and the German-based life science company, Evotec, announced today that they have updated the focus of their strategic collaboration to developing innovative precision treatments for cardiovascular diseases (CVDs). [Read more…]
Allogeneic iPSCs Gaining Momentum Due to Ease of Access and Economies of Scale
While autologous iPSC-based cell therapies are patient-specific, allogeneic iPSC-based cell therapies use donor-derived cells as a starting material. In recent years, a greater number of allogeneic iPSC-derived cell therapies are being studied than autologous therapies. One of the advantages of allogeneic therapy is that a large number of doses can be generated simultaneously from a single batch of iPSCs and banked. [Read more…]
- « Previous Page
- 1
- 2
- 3
- 4
- 5
- 6
- …
- 70
- Next Page »